Sarcoidosis‐like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response

Neoadjuvant chemoimmunotherapy has demonstrated improved efficacy and prognosis in stage IIa–IIIb patients with non‐small cell lung cancer (NSCLC). Drug‐induced sarcoidosis‐like reaction (DISR), an autoimmune reaction, has been reported as a type of immune‐related adverse event that may mimic diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuequan, Li, Ji, Chen, Minjiang, Liu, Hongsheng, Ma, Dongjie, Lin, Yuxiao, Wang, Mengzhao, Xu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671890/
https://www.ncbi.nlm.nih.gov/pubmed/34761878
http://dx.doi.org/10.1111/1759-7714.14228
Descripción
Sumario:Neoadjuvant chemoimmunotherapy has demonstrated improved efficacy and prognosis in stage IIa–IIIb patients with non‐small cell lung cancer (NSCLC). Drug‐induced sarcoidosis‐like reaction (DISR), an autoimmune reaction, has been reported as a type of immune‐related adverse event that may mimic disease progression. Here, we report the case of patient with NSCLC who developed DISR during neoadjuvant chemoimmunotherapy and finally achieved pathological complete response after surgery.

Ejemplares similares